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S U M M A R Y
Despite global efforts to reduce measles incidence, outbreaks continue to occur in developing countries
where HIV-1-infected adults represent a vulnerable population. Immunization campaigns have targeted
children, although little is known about the levels of measles protection in adult populations in Kenya.
The objective of this study was to determine seroprevalence and titers of measles IgG among HIV-1-
infected and uninfected adults in Nairobi, Kenya. The presence of anti-measles IgG was measured in
cryopreserved serum of 257 HIV-1-infected and 367 uninfected adults using a commercial ELISA
(Enzygnost, Germany). The measles IgG concentration was calculated for those samples that were
positive. Overall, 96% of adults were measles seropositive and the mean measles IgG concentration
among those who were seropositive was 4134 mIU/ml, which is well above previously reported
protective levels. There was no statistical difference in seroprevalence or antibody concentration
between the HIV-infected and HIV-uninfected groups. While local vaccination efforts and circulating
measles infection likely contribute to this high measles seroprevalence rate, these data are unique to an
urban population and may not reﬂect a country-wide distribution. Our results suggest that reduced
immunity among HIV-1-infected adults is not a major contributor to measles resurgence in Kenya.
 2013 The Authors. Published by Elsevier Ltd on behalf of International Society for Infectious
Diseases. 
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Despite large gains towards measles eradication in Africa, over
50 000 measles-related deaths occur yearly;1 2380 measles cases
were reported in Kenya in 2012, more than twice as many as in
2010.2,3While 24% of those affected were over the age of 15 years,3
efforts to accelerate measles control have primarily targeted
children.
Currently, there is little information on measles seroprevalence
among HIV-infected or HIV-uninfected adults in developing* Corresponding author.
E-mail address: merkel.michele@yahoo.com (M. Merkel).
1 These authors contributed equally to this work.
1201-9712       2013 The Authors. Published by Elsevier Ltd on behalf of International So
http://dx.doi.org/10.1016/j.ijid.2013.10.018countries. Few non-Western data exist and results vary: in Iran,
45% of previously vaccinated adults were measles seronegative4
compared to <5% in Yemen.5 According to the 2009 Kenya AIDS
Indicator Survey, over 7% of adults are HIV-infected; these
individuals may not have responded to vaccinations or may have
lost immunity.
2. Methods
Between 2007 and 2009, 470 HIV-1 discordant and 80 HIV
concordant negative couples were enrolled into a previously
described study in Nairobi, Kenya.6 For this retrospective study, an
equal number of HIV-infected males and females were selected.
An ELISA (Enzygnost, Germany) was used as per the manu-
facturer’s guidelines to measure anti-measles IgG in cryopreserved
sera. Samples were classiﬁed as: negative if OD450 was <0.1;
positive (protective) if >0.2; equivocal (non-positive) if 0.1 to 0.2.
Measles IgG seroprevalence and titers (mIU/ml) were calculated inciety for Infectious Diseases. Open access under CC BY-NC-SA license.
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tion with protective antibody between the HIV-infected and
uninfected groups was determined using Chi-square tests;
independent t-tests were used to compare measles-speciﬁc IgG
concentrations between groups. Stata IC/11 was used for the data
analyses and random sample selection.
3. Results
Measles-speciﬁc antibody was measured in 257 HIV-infected
and 367 uninfected adults in HIV discordant and HIV concordant
negative partnerships. Median age was 31 years (interquartile
range (IQR) 26–36). Three hundred and six (49%) of 624 lived in
formal housing, and individuals had a median of 2 (IQR 1–3) living
children. Among the HIV-infected, the median CD4+ T-cell count
was 404 cells/ml (IQR 271–571) and the median plasma viral load
was 4.6 log10 copies/ml (IQR 3.9–5.3) (Table 1). No participants
reported taking highly active antiretroviral therapy.
Overall, 599 (96%) adults had positive measles IgG (Table 2).
Positive measles IgG was observed in 246 (95.7%) HIV-infected
adults and 353 (96.2%) HIV-uninfected adults (p > 0.05). Of the
HIV-uninfected participants from HIV-1 discordant partnerships,
98.8% were measles seropositive compared to 90.5% from HIV
concordant negative partnerships (not statistically signiﬁcant).
Among HIV-infected adults, there was no difference between those
with a CD4 count greater or less than 250 cells/ml (data not shown).
The mean measles IgG concentration among those with positive
titers was 4134 mIU/ml (range 359–16 756). In the HIV-infected
and HIV-uninfected groups, of those with positive measles titers,
the mean IgG concentration was 3961 mIU/ml (range 359–16 756)
and 4255 mIU/ml (range 367–15 177), respectively (Table 2).
Among those with positive titers, there was no difference in
seroprevalence, mean antibody concentrations, age, or gender
between HIV-infected and uninfected individuals (data not
shown).Table 1
Demographic and clinical data by partnership status and gendera
HIV discordant partnershipb
Women (n = 254) Men (n = 254) 
HIV-positive 130 (51%) 127 (50%) 
Formal housing 132 (52%) 130 (51%) 
Lives with partner 245 (96%) 246 (97%) 
Age, years 29 (24–33) 35 (30–40) 
Years living with partner 5 (2–10) 5 (2–10) 
Number of living children 2 (1–3) 2 (1–3) 
Completed school years 8 (8–12) 12 (8–12) 
CD4 count (cells/ml)c 456 (299–634) 342 (238–493) 
Viral load (log10 copies/ml)
c 4.5 (3.7–5.0) 4.7 (4.0–5.4) 
IQR, interquartile range; NA, not applicable.
a Results are given as n (%) or median (IQR).
b Equal number of HIV-positive male and female partner couples chosen.
c Among those with HIV (n = 257)
Table 2





In HIV-1 discordant partnership 251 
In HIV concordant negative partnership 116 
Total 367 
Overall total 624 4. Discussion
While most measles seroprevalence studies focus on children,
this report investigates another important target group for whom
data are lacking: adults. In this urban cohort, measles seropreva-
lence was approximately 96% overall. These ﬁndings are higher
than previously reported values for measles seroprevalence among
Kenyan HIV-infected pregnant women; rates have ranged from
73% (1999–2004)7 to 94% (1996–1997).8 These differences could
be due to variations in geographic vaccination coverage.10
The average measles antibody concentration was 4134 mIU/ml,
higher than previously reported protection levels (>200 mIU/ml).
High antibody levels have been correlated with infection or viral
exposure, suggesting some protection observed here might be due
to exposure not solely vaccination.
We observed no difference in the proportion of individuals with
protective levels of measles antibody when comparing HIV-
infected and uninfected adult groups. This contrasts with a
previous study that showed only one-third of previously vaccinat-
ed HIV-1-infected antiretroviral-naı¨ve Kenyan children had
protective measles antibody levels.9 In our cohort, HIV-1 did not
result in depressed levels of protective measles antibodies, perhaps
because HIV was acquired during adulthood, not childhood. While
we observed a small difference in seroprevalence amongst the HIV-
uninfected groups, this was not statistically signiﬁcant.
Although the observed high measles seroprevalence is encour-
aging, it is notable that these data are unique to some adults in
Nairobi and not reﬂective of the entire country. Sustained
vaccination efforts, coupled with circulating measles in the
population have likely contributed to this high adult seropreva-
lence. Despite vaccination efforts, Kenya continues to experience
measles outbreaks; in 2011 in northern Kenya, 59% of cases were in
those 15 years or older,3 indicating measles protection is not
uniform throughout Kenya. Additionally, the HIV-uninfected
participants in concordant HIV-negative partnerships did not
meet the World Health Organization 95% herd immunity stipula-
tion to eliminate transmission. These data, in combination withHIV concordant negative partnership
Women (n = 58) Men (n = 58) Total (n = 624)
0 0 257 (41%)
18 (31%) 26 (45%) 306 (49%)
43 (74%) 43 (74%) 577 (92%)
25 (22–30) 28.5 (25–33) 31 (26–36)
3 (1–8) 3 (1–7) 4 (2–10)
1 (0–2) 1 (0–2) 2 (1–3)
12 (8–12) 12 (11–12) 11 (8–12)
NA NA 404 (271–571)
NA NA 4.6 (3.9–5.3)
 by HIV status and partnership
Protective antibodies, n (%) Mean IgG mIU/ml (range)
246 (95.7) 3961 (359–16 756)
248 (98.8) 4587 (379–15 177)
105 (90.5) 3471 (367–11 772)
353 (96.2) 4255 (367–15 177)
599 (96.0) 4134 (359–16 756)
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public health programs to diminish measles infection and identify
at-risk target populations in Kenya and the region.
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